VitriVax says it closed $87M Series C co-led by F-Prime, NEA, RA Capital and Sanofi Ventures

· VC Investment

TLDR

  • VitriVax says it closed an $87M Series C co-led by F-Prime, NEA, RA Capital and Sanofi Ventures; Eli Lilly participated.1
  • The money funds a first-in-human trial of its single-dose Lyme vaccine candidate, which is not yet in the clinic.1
  • No Lyme vaccine is approved; the release names no candidate and gives no trial start date.12

VitriVax, a Boulder, Colorado vaccine developer, announced on 18 November 2026 "the close of an oversubscribed $87 million Series C financing", according to its Business Wire release.1 The round was "co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and Company as well as other existing investors".1 The release does not say which co-leads are new to the company. RA Capital co-led the $17.25M Series B with Adjuvant Capital, so it is at least an existing backer.3 Axios Pro ran the news as an exclusive with chief executive Romulo Colindres and reported the $87M Series C.2 Valuation and individual investment sizes were not disclosed in the release or the visible part of the Axios Pro report.

The money is for VitriVax's lead programme, "a Lyme disease vaccine candidate with a novel mechanism of action", which the company plans to take into its "first-in-human clinical trial", and for expanding its pipeline.1 The candidate is therefore not yet in the clinic: the release says only that VitriVax has "progressed cGMP manufacturing readiness for Phase 1 clinical trials".1 It gives no candidate name, antigen, trial start date, size or location. The programme rests on the company's ALTA platform (Atomic Layering Thermostable Antigen and Adjuvant), which the company says is aimed at single-dose, thermostable vaccines.1 The company also says there is no approved human Lyme vaccine, that other candidates rely on multi-dose regimens, and that, across vaccines, up to half of patients fail to complete multi-dose regimens, a figure for which the release gives no source. These statements are company-reported.1

The Series C follows the $17.25M Series B, which the release says was completed in September 2025 and which VitriVax announced on 22 October 2025.13 On our arithmetic, the new round is about five times the Series B. The release also lists non-dilutive support from the Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and "a multi-year contract with the U.S. Department of Defense", and names other programmes in rabies (CEPI), melioidosis (DTRA), polio and HIV (Gates Foundation).1 In July 2023 VitriVax won a $29M, five-year contract from the Defense Threat Reduction Agency for single-shot melioidosis and glanders vaccines, and VitriVax's Kimberly Erickson told Global Biodefense the company hoped the technology would "benefit both military personnel and the general population".4 Whether any defence money supports the Lyme programme is not stated.

Axios Pro notes that no Lyme vaccine is currently approved, though Pfizer and Moderna have clinical-stage candidates.2 On the sources cited, the furthest advanced is Pfizer and Valneva's PF-07307405 (VLA15). On 14 August 2026 Pfizer said the European Medicines Agency had validated its marketing authorisation application, citing efficacy of more than 70 per cent in the Phase 3 VALOR trial.5 Fierce Biotech reported in April that efficacy was 73.2 per cent but the lower bound of the confidence interval, 15.8 per cent, fell below the 20 per cent threshold, so the primary endpoint was technically missed.6 Valneva's chief executive argued that the 20 per cent bound was a protocol choice and noted that a day-1 post-booster endpoint cleared it, with a lower bound of 21.7 per cent.6 BioSpace reported on 4 November that a European verdict is expected in 2027 and that Pfizer's discussions with the US regulator continue.7 VitriVax has yet to dose a person, so any comparison with that programme is prospective.

RA Capital, which has now co-led two VitriVax rounds, also led ILiAD Biotechnologies' $115M Series B in February 2026 for its intranasal BPZE1 pertussis vaccine.8 Other vaccine investments by F-Prime, NEA and Sanofi Ventures were not verified for this article.

Why it matters: an $87M round with four co-leads according to the company, about five times the previous round by our arithmetic, backs a single-dose Lyme vaccine that has not yet entered human trials, while the nearest rival awaits a 2027 European verdict and VitriVax's technical claims remain company-reported.137

Sources

  1. VitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand Pipeline (Business Wire (VitriVax))
  2. Exclusive: VitriVax raises $87M Series C for Lyme disease vaccine (Axios Pro)
  3. VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform - VitriVax: Eliminating barriers to global vaccination (VitriVax)
  4. VitriVax Wins DoD Contract to Develop Single-Shot Vaccine for Melioidosis and Glanders (Global Biodefense)
  5. Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency (Pfizer)
  6. Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn't tell the whole story (Fierce Biotech)
  7. Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US (BioSpace)
  8. ILiAD Biotechnologies: $115 Million Series B Closed To Advance Intranasal Pertussis Vaccine (Pulse 2)